Panacea Index Logo

Command Palette

Search for a command to run...

Smoking cessation improves cardiometabolic risk in overweight and obese subjects treated with varenicline and dietary counseling.

Nutrition, metabolism, and cardiovascular diseases : NMCD
April 1, 2017
E Heggen et al. (3 authors)
Journal ArticleRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether dietary counseling could mitigate adverse cardiometabolic effects (e.g., weight gain, dyslipidemia, blood pressure changes) in overweight and obese smokers attempting to quit.

Results Summary

Dietary counseling during smoking cessation led to improved triglyceride levels and diastolic blood pressure in quitters without significant weight gain, though other cardiometabolic markers and insulin resistance showed no difference between quitters and continuing smokers. The study combined low-carbohydrate and low-fat diet groups due to similar outcomes.

Population

Overweight and obese smokers (BMI 25-40 kg/m², ≥10 cigarettes/day).

Effective Dosage

Not specified (dietary counseling focused on low-carbohydrate or low-fat diets).

Duration

12 weeks.

Interactions

None mentioned.

Extracted Claims (12)
InterventionDirectionEndpointPopulationDosageImpactClaim #
low-carbohydrate or low-fat diet with varenicline
no change
changes in metabolic risk factors
smokers (≥10 cigarettes/day) with BMI 25-40 kg/m2
-
did not differ
#1
low-carbohydrate or low-fat diet with varenicline
no change
weight change
validated quitters vs continuing smokers
-0.1 ± 3.0 kg vs 0.3 ± 3.1 kg
similar
#2
low-carbohydrate or low-fat diet with varenicline
no change
change in waist circumference
validated quitters vs continuing smokers
-2.0 ± 3.8 cm vs -0.9 ± 3.9 cm
similar
#3
low-carbohydrate or low-fat diet with varenicline
decrease
triglyceride concentrations
quitters
-0.16 ± 0.52 mmol/l vs 0.21 ± 0.95 mmol/l
more favorable
#4
low-carbohydrate or low-fat diet with varenicline
decrease
diastolic blood pressure
quitters
-0.9 ± 6 mmHg vs 1.9 ± 8 mmHg
more favorable
#5
low-carbohydrate or low-fat diet with varenicline
no change
changes in other cardiometabolic risks
quitters and continuous smokers
-
did not differ
#6
low-carbohydrate or low-fat diet with varenicline
no change
HOMA-IR
quitters and continuous smokers
-
did not differ
#7
low-carbohydrate or low-fat diet with varenicline
no change
energy intake
quitters and continuous smokers
-
did not differ
#8
low-carbohydrate or low-fat diet with varenicline
no change
resting metabolic rate
quitters and continuous smokers
-
did not differ
#9
dietary intervention
decrease
dyslipidemia
overweight and obese smokers
-
improved
#10
dietary intervention
decrease
blood pressure
overweight and obese smokers
-
improved
#11
dietary intervention
no change
weight
quitters
-
no early weight gain was seen
#12
Abstract

BACKGROUND AND AIM: Weight gain after stopping smoking potentially counteracts improvements in cardiometabolic risks. We investigated changes in metabolic syndrome (MetS) components and homeostasis assessment model insulin resistance (HOMA-IR) in smokers given dietary counseling during their quit attempt. METHODS AND RESULTS: Smokers (≥10 cigarettes/day) with BMI 25-40 kg/m2 were randomized to a low-carbohydrate or low-fat diet and treated with a standard course of varenicline for 12 weeks. Quitters were assessed according to the Russell standard (≤5 cigarettes after the quit date) validated with expired breath carbon monoxide (CO) < 10 ppm. Of 122 randomized participants, 108 (89%) completed clinical and laboratory assessments at 12 weeks. As changes in metabolic risk factors did not differ between dietary groups, we combined the groups to compare quitters to continuing smokers. We found similar weight change among 78 validated quitters as 30 continuing smokers (-0.1 ± 3.0 kg vs 0.3 ± 3.1 kg; p = 0.7) and change in waist circumference (-2.0 ± 3.8 cm vs -0.9 ± 3.9 cm; p = 0.2). Changes in triglyceride concentrations (-0.16 ± 0.52 mmol/l vs 0.21 ± 0.95 mmol/l; p = 0.015) and diastolic blood pressure (-0.9 ± 6 mmHg vs 1.9 ± 8 mmHg; p = 0.039) were more favorable in quitters. Changes in other cardiometabolic risks and HOMA-IR did not differ between quitters and continuous smokers, nor did energy intake or resting metabolic rate. CONCLUSION: Dyslipidemia and blood pressure improved and no early weight gain was seen in quitters, suggesting that dietary intervention can mitigate some of the effects of stopping smoking on cardiometabolic risk factors in overweight and obese smokers. CLINICAL TRIALS REGISTRATION: NCT01069458.

Medical Subject Headings (MeSH)
AdultBiomarkersBlood PressureCounselingFemaleHumansInsulin ResistanceMaleMetabolic SyndromeMiddle AgedNicotinic AgonistsNorwayObesityPrevalenceRisk AssessmentRisk FactorsSmokingSmoking CessationSmoking PreventionTime FactorsTreatment OutcomeTriglyceridesVareniclineWeight Loss
Study Links
Quality Scores
SafetyNot Assessed
Efficacy70/10
Quality80/10
Citation Metrics
Total Citations9
Citations/Year1.1
Relative Citation Ratio0.42
NIH Percentile22.5%
Research Impact Scores
APT Score0.50
Weight Score1.88
Normalized Score0.64
Related Supplements
Smoking cessation improves cardiometabolic risk in overweigh... | Panacea Index